These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
46. Care of type 2 diabetes: where do the new medications fit? Clem CO; Heins JR S D Med; 2015 Mar; 68(3):126-7. PubMed ID: 25906502 [No Abstract] [Full Text] [Related]
47. Xenopus GLP-1-based glycopeptides as dual glucagon-like peptide 1 receptor/glucagon receptor agonists with improved in vivo stability for treating diabetes and obesity. Li Q; Yang Q; Han J; Liu X; Fu J; Yin J Chin J Nat Med; 2022 Nov; 20(11):863-872. PubMed ID: 36427920 [TBL] [Abstract][Full Text] [Related]
48. The development of non-peptide glucagon-like peptide-1 receptor agonist for the treatment of type 2 diabetes. Moon HS; Kim MK; Son MH Arch Pharm Res; 2011 Jul; 34(7):1041-3. PubMed ID: 21811909 [TBL] [Abstract][Full Text] [Related]
49. Dual GIP/GLP-1 receptor agonists: New advances for treating type-2 diabetes. Scheen AJ Ann Endocrinol (Paris); 2023 Apr; 84(2):316-321. PubMed ID: 36639119 [TBL] [Abstract][Full Text] [Related]
51. GLP-1 agonists: US sees 700% increase over four years in number of patients without diabetes starting treatment. Mahase E BMJ; 2024 Jul; 386():q1645. PubMed ID: 39043396 [No Abstract] [Full Text] [Related]
52. Exenatide for the treatment of type 2 diabetes mellitus. Ruddock B Issues Emerg Health Technol; 2005 Aug; (71):1-4. PubMed ID: 16389694 [TBL] [Abstract][Full Text] [Related]
53. Efficacy and safety of glucagon-like peptide-1 agonists on macrovascular and microvascular events in type 2 diabetes mellitus: A meta-analysis. Gargiulo P; Savarese G; D'Amore C; De Martino F; Lund LH; Marsico F; Dellegrottaglie S; Marciano C; Trimarco B; Perrone-Filardi P Nutr Metab Cardiovasc Dis; 2017 Dec; 27(12):1081-1088. PubMed ID: 29113708 [TBL] [Abstract][Full Text] [Related]
54. Effects of exenatide on systolic blood pressure in subjects with type 2 diabetes. Okerson T; Yan P; Stonehouse A; Brodows R Am J Hypertens; 2010 Mar; 23(3):334-9. PubMed ID: 20019672 [TBL] [Abstract][Full Text] [Related]
55. Therapies for inter-relating diabetes and obesity - GLP-1 and obesity. Iepsen EW; Torekov SS; Holst JJ Expert Opin Pharmacother; 2014 Dec; 15(17):2487-500. PubMed ID: 25260877 [TBL] [Abstract][Full Text] [Related]
56. Glucagon-like peptide-1 analogs: Miracle drugs are blooming? Gong B; Yao Z; Zhou C; Wang W; Sun L; Han J Eur J Med Chem; 2024 Apr; 269():116342. PubMed ID: 38531211 [TBL] [Abstract][Full Text] [Related]
58. [Modulation of the incretin effect in the treatment of diabetes]. Vidal J Med Clin (Barc); 2014; 143 Suppl 2():8-11. PubMed ID: 25326837 [TBL] [Abstract][Full Text] [Related]
59. Diabetes: Concerns about long-term use of GLP-1 analogues. Holmes D Nat Rev Endocrinol; 2016 Apr; 12(4):186. PubMed ID: 26939977 [No Abstract] [Full Text] [Related]